Stockwinners Market Radar for January 22, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

Settings & Search

CRM...		Hot Stocks 20:00 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Activist investor Elliott Management has made a multibillion-dollar investment in Salesforce (CRM), adding to the pressures facing the business-software provider, The Wall Street Journal's Lauren Thomas and Laura Cooper report, citing people familiar with the matter. "Salesforce is one of the preeminent software companies in the world, and having followed the company for nearly two decades, we have developed a deep respect for [Co-Chief Executive] Marc Benioff and what he has built," Jesse Cohn, managing partner at Elliott, said. "We look forward to working constructively with Salesforce to realize the value befitting a company of its stature," added Cohn. 2. Abbott Laboratories (ABT) said it's cooperating with the Justice Department in a probe involving the contamination of baby formula at one of the company's plants last year, Bloomberg's Madison Muller and Anna Edney report. "DOJ has informed us of its investigation and we're cooperating fully," Abbott spokesman Scott Stoffel said in an email. 3. With a promising near-term outlook followed by a coming transition to electric vehicles that should juice sales volumes, Ferrari shares (RACE) appear set to shift into higher gear in 2023, Nicholas Jasinski writes in this week's edition of Barron's. 4. Disney's (DIS) "Avatar: The Way of Water" won the long weekend with an estimated $40.6M for a domestic total of $572.4M. Globally, the movie has crossed the $1.9B mark, as the James Cameron's sequel becomes the 13th highest-grossing film of all time at the U.S. box office. 5. Wells Fargo (WFC), Disney, Calumet Specialty Products Partners (CLMT), Philip Morris (PM), Altria Group (MO), Energy Transfer (ET), ConocoPhillips (COP), Halliburton (HAL), CVR Energy (CVI), NOW (DNOW), and NexTier Oilfield Solutions (NEX) saw positive mentions in this week's edition of Barron's.
ANET...		Hot Stocks 19:25 EST Amazon Web Services plans to invest $35B in Virginia by 2040 - Governor Glenn Youngkin announced on January 20 that Amazon Web Services, an Amazon.com (AMZN) company, plans to invest $35B by 2040 to establish multiple data center campuses across Virginia. Numerous localities in the Commonwealth are under consideration and will be decided at a later date, the governor's office stated. "These new campuses will combine expandable capacity to position AWS for long-term growth in the Commonwealth. Amazon is among the largest private-sector employers in the Commonwealth of Virginia, establishing its first AWS data centers and operations facilities in 2006 and later announcing its second headquarters in Arlington in 2018. This announcement of planned investment will create at least 1,000 total new jobs across Virginia," Youngkin said. "AWS has a significant presence in Virginia, and we are excited that AWS has chosen to continue their growth and expand their footprint across the Commonwealth," said Governor Glenn Youngkin. "Virginia will continue to encourage the development of this new generation of data center campuses across multiple regions of the Commonwealth. These areas offer robust utility infrastructure, lower costs, great livability, and highly educated workforces and will benefit from the associated economic development and increased tax base, assisting the schools and providing services to the community." Stocks that had moved higher following the news included Nvidia (NVDA) and Arista Networks (ANET). Reference Link
AMZN		Hot Stocks 19:25 EST Correction: Amazon Web Services plans to invest $35B in Virginia by 2040
AMZN		Hot Stocks 19:25 EST Amazon Web Services plans to invest $35B in Virginia by 2040 - Governor Glenn Youngkin announced that Amazon Web Services, an Amazon.com company, plans to invest $35B by 2040 to establish multiple data center campuses across Virginia. Numerous localities in the Commonwealth are under consideration and will be decided at a later date. These new campuses will combine expandable capacity to position AWS for long-term growth in the Commonwealth. Amazon is among the largest private-sector employers in the Commonwealth of Virginia, establishing its first AWS data centers and operations facilities in 2006 and later announcing its second headquarters in Arlington in 2018. This announcement of planned investment will create at least 1,000 total new jobs across Virginia, Youngkin said. "AWS has a significant presence in Virginia, and we are excited that AWS has chosen to continue their growth and expand their footprint across the Commonwealth," said Governor Glenn Youngkin. "Virginia will continue to encourage the development of this new generation of data center campuses across multiple regions of the Commonwealth. These areas offer robust utility infrastructure, lower costs, great livability, and highly educated workforces and will benefit from the associated economic development and increased tax base, assisting the schools and providing services to the community." Reference Link
MNK		Hot Stocks 16:46 EST Mallinckrodt presents new TERLIVAZ for injection data on HRS reversal - Mallinckrodt announced the presentation of results from a retrospective analysis of three North American-centric, Phase III, randomized, placebo-controlled studies comparing the incidence of hepatorenal syndrome reversal with baseline acute-on-chronic liver failure grade in adults with rapid reduction in kidney function treated with TERLIVAZ plus albumin versus those treated with placebo plus albumin. TERLIVAZ is the first and only FDA-approved product indicated for the treatment of adults with HRS involving rapid reduction in kidney function, an acute and life-threatening condition requiring hospitalization. Terlipressin is recommended by the American Association for the Study of Liver Diseases guidance and the American College of Gastroenterology guidelines. The retrospective analysis used pooled data from the OT-0401, REVERSE, and CONFIRM Phase III studies to compare the incidence of HRS reversal by baseline ACLF grade in patients treated with terlipressin plus albumin versus placebo plus albumin for up to 14 days. Severity of ACLF was graded according to the number of organ failures. The incidence of HRS reversal was defined as at least one serum creatinine value of less than or equal to1.5 mg/dL while on treatment.
PLRX		Hot Stocks 16:08 EST Pliant Therapeutics announces data from INTEGRIS-IPF Phase 2a trial - Pliant Therapeutics announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis. The 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period and displayed a favorable pharmacokinetic profile. The trial's exploratory efficacy endpoints assessed changes in forced vital capacity, Quantitative Lung Fibrosis imaging and biomarkers. Bexotegrast at 320 mg demonstrated a statistically significant mean increase in FVC from baseline at all timepoints, surpassing all lower dose cohorts, and showed a strong treatment effect on FVC percent predicted, QLF and profibrotic biomarkers versus placebo at 12 weeks. The INTEGRIS-IPF Phase 2a trial is evaluating bexotegrast at once-daily doses of 40 mg, 80 mg, 160 mg, 320 mg or placebo for 12 weeks in 119 patients with IPF. The 320 mg group enrolled 21 patients in the active arm and 8 patients in the placebo arm. Comparable to the lower dose groups, approximately 80% of all enrolled patients were on standard of care and were equally distributed between nintedanib and pirfenidone. The 320 mg group will continue until all patients have been treated for at least 24 weeks, with final data expected in the second quarter of 2023.